UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 128

Sortiert nach

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial

European heart journal, 2013-10, Vol.34 (40), p.3137-3144

2013

Volltextzugriff (PDF)

Erratum. Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care 2020;44:2853-2858

Diabetes care, 2022-10, Vol.45 (10), p.2476-2476

2022

Volltextzugriff (PDF)

Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population

Diabetes care, 2020-11, Vol.43 (11), p.2853-2858

2020

Volltextzugriff (PDF)

Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

European heart journal, 2024-04, Vol.45 (15), p.1371-1374

2024

Volltextzugriff (PDF)

Risk factor reduction in type 2 diabetes demands a multifactorial approach

European journal of preventive cardiology, 2019-12, Vol.26 (2_suppl), p.81-91

2019

Volltextzugriff (PDF)

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis

Diabetes care, 2022-10, Vol.45 (10), p.e146-e147

2022

Volltextzugriff (PDF)

High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk Factors

Diabetes care, 2024-02, Vol.47 (2), p.246-251

2024

Volltextzugriff (PDF)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Cardiovascular diabetology, 2023-08, Vol.22 (1), p.1-220, Article 220

2023

Volltextzugriff (PDF)

Implantable cardioverter defibrillator and cardiac resynchronization treatment in people with type 2 diabetes: a comparison with age- and sex matched controls from the general population

Cardiovascular diabetology, 2024-01, Vol.23 (1), p.18-18, Article 18

2024

Volltextzugriff (PDF)

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial

European heart journal, 2008-01, Vol.29 (2), p.166-176

2008

Volltextzugriff (PDF)

Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort

Cardiovascular diabetology, 2022-07, Vol.21 (1), p.1-129, Article 129

2022

Volltextzugriff (PDF)

Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design

International journal of cardiology, 2020-08, Vol.313, p.76-82

2020

Volltextzugriff (PDF)

Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction: A report from the DIGAMI 2 trial

Diabetes care, 2012-04, Vol.35 (4), p.911-917

2012

Volltextzugriff (PDF)

Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial

European journal of heart failure, 2024-05, Vol.26 (8), p.1727-1735

2024

Volltextzugriff (PDF)

Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states

Cardiovascular diabetology, 2024-01, Vol.23 (1), p.25-25, Article 25

2024

Volltextzugriff (PDF)

Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry

Diabetes research and clinical practice, 2022-01, Vol.183, p.109156-109156

2022

Volltextzugriff (PDF)

Inflammatory bowel disease and cardiovascular diseases: a concise review

European heart journal open, 2022-01, Vol.2 (1), p.oeab029-oeab029

2022

Volltextzugriff (PDF)

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study

Cardiovascular diabetology, 2022-09, Vol.21 (1), p.1-195, Article 195

2022

Volltextzugriff (PDF)

Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG

Clinical therapeutics, 2016-06, Vol.38 (6), p.1279-1287

2016

Volltextzugriff (PDF)

Effect of dipeptidyl peptidase‐4 inhibitors on complement activation

Diabetes/metabolism research and reviews, 2021-03, Vol.37 (3), p.e3385-n/a

2021

Volltextzugriff (PDF)

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys

Cardiovascular diabetology, 2021-02, Vol.20 (1), p.38-38, Article 38

2021

Volltextzugriff (PDF)

Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial

European journal of preventive cardiology, 2019-05, Vol.26 (8), p.847-854

2019

Volltextzugriff (PDF)

Enhanced External Counterpulsation for Management of Postacute Sequelae of SARS-CoV-2 Associated Microvascular Angina and Fatigue: An Interventional Pilot Study

Cardiology research and practice, 2023-12, Vol.2023, p.6687803-9

2023

Volltextzugriff (PDF)

Changes in vascular function and correlation with cardiotoxicity in women with newly diagnosed breast cancer undergoing HER2-directed therapy with and without anthracycline/cyclophosphamide

European heart journal open, 2024-01, Vol.4 (1), p.oead130-oead130

2024

Volltextzugriff (PDF)

Ceramides: a potential cardiovascular biomarker in young adult childhood cancer survivors?

European heart journal open, 2024-03, Vol.4 (2), p.oeae026-oeae026

2024

Volltextzugriff (PDF)

1 – 25 von 128

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(120)
Mit Volltextzugriff
(120)

Publikationsform

Artikel
(127)
Dissertationen
(1)

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(95)
Science & Technology
(85)
Life Sciences & Biomedicine
(84)
Humans
(62)
Cardiovascular System & Cardiology
(55)
Risk Factors
(47)
Cardiac & Cardiovascular Systems
(41)
Endocrinology & Metabolism
(40)
Diabetes
(39)
Female
(37)
Male
(37)
Diabetes Mellitus
(34)
Cardiovascular Disease
(31)
Aged
(29)
Myocardial Infarction
(29)
Prognosis
(28)
Middle Aged
(27)
Diabetes Mellitus, Type 2 - Complications
(24)
Diabetes Mellitus, Type 2 - Drug Therapy
(22)
Cardiovascular Diseases
(21)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial

Erratum. Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population. Diabetes Care 2020;44:2853-2858

Patients With Type 2 Diabetes Have an Increased Demand for Pacemaker Treatment: A Comparison With Age- and Sex-Matched Control Subjects From the General Population

Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials

Risk factor reduction in type 2 diabetes demands a multifactorial approach

Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis

High Mannose Correlates With Surrogate Indexes of Insulin Resistance and Is Associated With an Increased Risk of Cardiovascular Events Independently of Glycemic Status and Traditional Risk Factors

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Implantable cardioverter defibrillator and cardiac resynchronization treatment in people with type 2 diabetes: a comparison with age- and sex matched controls from the general population

The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial

Mannose-binding lectin does not explain the dismal prognosis after an acute coronary event in dysglycaemic patients. A report from the GAMI cohort

Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design

Complement Activation and Prognosis in Patients With Type 2 Diabetes and Myocardial Infarction: A report from the DIGAMI 2 trial

Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: Results from the phase 2b MIRACLE trial

Sex differences in the association between insulin resistance and non-fatal myocardial infarction across glycaemic states

Saving time by replacing the standardised two-hour oral glucose tolerance test with a one-hour test: Validation of a new screening algorithm in patients with coronary artery disease from the ESC-EORP EUROASPIRE V registry

Inflammatory bowel disease and cardiovascular diseases: a concise review

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study

Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG

Effect of dipeptidyl peptidase‐4 inhibitors on complement activation

Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys

Testosterone, sex hormone-binding globulin and risk of cardiovascular events: A report from the Outcome Reduction with an Initial Glargine Intervention trial

Enhanced External Counterpulsation for Management of Postacute Sequelae of SARS-CoV-2 Associated Microvascular Angina and Fatigue: An Interventional Pilot Study

Changes in vascular function and correlation with cardiotoxicity in women with newly diagnosed breast cancer undergoing HER2-directed therapy with and without anthracycline/cyclophosphamide

Ceramides: a potential cardiovascular biomarker in young adult childhood cancer survivors?

Suchergebnisse filtern